1
0
0
(1 - 26 von 37
)
Macrophage Migration Inhibitory Factor Coordinates DNA ...Taylor & Francis Online
www.tandfonline.com
von A Nemajerova · · Zitiert von: 50 — ,. Ute M. Moll. ,. Oleksi Petrenko. &. Günter Fingerle-Rowson. Pages | Published online: 01 May Cite this article · https://doi.org cc. von A Nemajerova · · Zitiert von: 50 — ,. Ute M. Moll. ,. Oleksi Petrenko. &. Günter Fingerle-Rowson. Pages | Published online: 01 May Cite this article · https://doi.org cc.
Combination therapy with the type II anti-CD20 antibody ...Taylor & Francis Online
www.tandfonline.com
von C Klein · · Zitiert von: 8 — Günter Fingerle-RowsonPharma Development Clinical Oncology, F. Hoffmann-La Roche Ltd, Basel, SwitzerlandView further author information. Pages von C Klein · · Zitiert von: 8 — Günter Fingerle-RowsonPharma Development Clinical Oncology, F. Hoffmann-La Roche Ltd, Basel, SwitzerlandView further author information. Pages
Molecular and Cellular BiologyTaylor & Francis Online
www.tandfonline.com
von G Fingerle-Rowson · · Zitiert von: 138 — Günter Fingerle-Rowson1 Clinic I for Internal Medicine, Hematology and Oncology, University Hospital Cologne, Cologne, Germany.
American Journal of Hematology | Blood Research JournalWiley Online Library
onlinelibrary.wiley.com
von O Al‐Sawaf · · Zitiert von: 7 — ... Günter Fingerle-Rowson,. Günter Fingerle-Rowson. F. Hoffmann-La Roche, Basel, Switzerland. Search for more papers by this author · Stephan ... von O Al‐Sawaf · · Zitiert von: 7 — ... Günter Fingerle-Rowson,. Günter Fingerle-Rowson. F. Hoffmann-La Roche, Basel, Switzerland. Search for more papers by this author · Stephan ...
Discovery and Development of Obinutuzumab (GAZYVA ...Wiley Online Library
onlinelibrary.wiley.com
von C Klein · · Zitiert von: 1 — Günter Fingerle-Rowson,. Günter Fingerle-Rowson. Pharma Development Oncology, F. Hoffmann-La Roche, Basel, Switzerland. Search for more papers ... von C Klein · · Zitiert von: 1 — Günter Fingerle-Rowson,. Günter Fingerle-Rowson. Pharma Development Oncology, F. Hoffmann-La Roche, Basel, Switzerland. Search for more papers ...
Delayed development of chronic lymphocytic leukemia in the ...ashpublications.org
ashpublications.org
von N Reinart · · Zitiert von: 110 — Günter Fingerle-Rowson. Günter Fingerle-Rowson. 1Department I of Internal Medicine, University Hospital Cologne, and Center for Integrated Oncology Köln-Bonn ... von N Reinart · · Zitiert von: 110 — Günter Fingerle-Rowson. Günter Fingerle-Rowson. 1Department I of Internal Medicine, University Hospital Cologne, and Center for Integrated Oncology Köln-Bonn ...
Obinutuzumab or Rituximab Plus Cyclophosphamide, ...Swiss Open Access Repository
sonar.ch
von U Vitolo · · Zitiert von: 420 — Oestergaard, Günter Fingerle-Rowson, Olivier Catalani, and Tina Nielsen, F. Hoffman-La Roche, Basel, Switzerland; and Michael Wenger ... von U Vitolo · · Zitiert von: 420 — Oestergaard, Günter Fingerle-Rowson, Olivier Catalani, and Tina Nielsen, F. Hoffman-La Roche, Basel, Switzerland; and Michael Wenger ...
MIF coordinates the cell cycle with DNA damage checkpoints ...BioMed Central
celldiv.biomedcentral.com
von G Fingerle-Rowson · · Zitiert von: 48 — MIF coordinates the cell cycle with DNA damage checkpoints. Lessons from knockout mouse models. Günter Fingerle-Rowson &; Oleksi Petrenko. Cell ... von G Fingerle-Rowson · · Zitiert von: 48 — MIF coordinates the cell cycle with DNA damage checkpoints. Lessons from knockout mouse models. Günter Fingerle-Rowson &; Oleksi Petrenko. Cell ...
Treatment of Indolent Lymphoma in GermanyScienceDirect.com
www.sciencedirect.com
von C Schmidt · · Zitiert von: 11 — , Lenka Kellermann 7 , Wolfgang Hiddemann 1 , Guenter Fingerle-Rowson 8 , Martin Dreyling 1. Show more. Add to Mendeley. Share. Cite. https://doi.org von C Schmidt · · Zitiert von: 11 — , Lenka Kellermann 7 , Wolfgang Hiddemann 1 , Guenter Fingerle-Rowson 8 , Martin Dreyling 1. Show more. Add to Mendeley. Share. Cite. https://doi.org
Health Related Quality of Life (HRQOL) in Patients ...ScienceDirect
www.sciencedirect.com
von BF Eichhorst · · Zitiert von: 7 — Barbara F. Eichhorst, MD,1 Kirsten Fischer,*,2 Anna- Maria Fink, MD,*,3 Guenter Fingerle-Rowson, MD, PhD,*,4 Anne Westermann,*,5 Clemens- Martin Wendtner, ...
A Review of Obinutuzumab (GA101), a Novel Type II Anti- ...Springer
link.springer.com
von K Tobinai · · Zitiert von: 168 — Günter Fingerle-Rowson is an employee at F. Hoffmann-La Roche Ltd. and owns stock in F. Hoffmann-La Roche Ltd. Compliance with Ethics ... von K Tobinai · · Zitiert von: 168 — Günter Fingerle-Rowson is an employee at F. Hoffmann-La Roche Ltd. and owns stock in F. Hoffmann-La Roche Ltd. Compliance with Ethics ...
Expansion of CD14+CD16+Monocytes in Critically Ill ...Springer
link.springer.com
von G Fingerle-Rowson · · Zitiert von: 109 — Authors and Affiliations. Department of Internal Medicine I, Klinikum Grosshadern, University of Muenchen, Muenchen, FRG. Günter Fingerle-Rowson & Jens Auers. von G Fingerle-Rowson · · Zitiert von: 109 — Authors and Affiliations. Department of Internal Medicine I, Klinikum Grosshadern, University of Muenchen, Muenchen, FRG. Günter Fingerle-Rowson & Jens Auers.
MRD response in relapsed/refractory FL after ...Nature Journal
www.nature.com
von C Pott · · Zitiert von: 19 — Nathalie Spielewoy, Guenter Fingerle-Rowson, Kirsten Mundt & Elisabeth Wassner-Fritsch. Roche, Welwyn Garden City, UK. Chris Harbron.
"MRD response in relapsed/refractory FL after ...Digital Commons@Becker
digitalcommons.wustl.edu
von C Pott · · Zitiert von: 29 — ... Guenter Fingerle-Rowson, F. Hoffmann-La Roche Ltd · Chris Harbron, Roche · Kirsten Mundt, F. Hoffmann-La Roche Ltd · Elisabeth Wassner-Fritsch, ... von C Pott · · Zitiert von: 29 — ... Guenter Fingerle-Rowson, F. Hoffmann-La Roche Ltd · Chris Harbron, Roche · Kirsten Mundt, F. Hoffmann-La Roche Ltd · Elisabeth Wassner-Fritsch, ...
Influence of Chemotherapy on Efficacy and SafetyResearch Explorer The University of Manchester
research.manchester.ac.uk
von W Hiddemann · · Zitiert von: 220 — ... Günter Fingerle-rowson, Marcel Wolbers, Tina Nielsen, Robert E. Marcus. Division of Cancer Sciences (L5). Research output: Contribution to journal › Article ... von W Hiddemann · · Zitiert von: 220 — ... Günter Fingerle-rowson, Marcel Wolbers, Tina Nielsen, Robert E. Marcus. Division of Cancer Sciences (L5). Research output: Contribution to journal › Article ...
MIF coordinates the cell cycle with DNA damage ...National Institutes of Health (NIH) (.gov)
pubmed.ncbi.nlm.nih.gov
von G Fingerle-Rowson · · Zitiert von: 48 — doi: Authors. Günter Fingerle-Rowson , Oleksi Petrenko. Affiliation. 1 University Hospital Cologne, Clinic I of Internal Medicine ... von G Fingerle-Rowson · · Zitiert von: 48 — doi: Authors. Günter Fingerle-Rowson , Oleksi Petrenko. Affiliation. 1 University Hospital Cologne, Clinic I of Internal Medicine ...
Macrophage Migration Inhibitory Factor Enzymatic Activity, ...ATS Journals
www.atsjournals.org
von H Adamali · · Zitiert von: 64 — , Günter Fingerle-Rowson. x. Günter Fingerle-Rowson. Search for articles by this author. , Richard J. Bucala. x. Richard J. Bucala. Search for ... von H Adamali · · Zitiert von: 64 — , Günter Fingerle-Rowson. x. Günter Fingerle-Rowson. Search for articles by this author. , Richard J. Bucala. x. Richard J. Bucala. Search for ...
Macrophage migration inhibitory factor protects from ...National Institutes of Health (NIH) (.gov)
pubmed.ncbi.nlm.nih.gov
von T Brocks · · Zitiert von: 28 — ... Guenter Fingerle-Rowson. Affiliations. 1 Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany. 2 Center for Integrated ... von T Brocks · · Zitiert von: 28 — ... Guenter Fingerle-Rowson. Affiliations. 1 Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany. 2 Center for Integrated ...
Obinutuzumab plus bendamustine versus ...Masarykova univerzita
www.muni.cz
von LH Sehn · · Zitiert von: 371 — ... Günter FINGERLE-ROWSON and Bruce D CHESON. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non ... von LH Sehn · · Zitiert von: 371 — ... Günter FINGERLE-ROWSON and Bruce D CHESON. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non ...
Randomized Phase II Trial Comparing Obinutuzumab ...Europe PMC
europepmc.org
von LH Sehn · · Zitiert von: 179 — ... Günter Fingerle-Rowson, Roche, Basel, Switzerland; Akiko Chai, Genentech BioOncology, South San Francisco, CA; Oliver Press, Fred Hutchinson Cancer Research ... von LH Sehn · · Zitiert von: 179 — ... Günter Fingerle-Rowson, Roche, Basel, Switzerland; Akiko Chai, Genentech BioOncology, South San Francisco, CA; Oliver Press, Fred Hutchinson Cancer Research ...
Risk of HBV reactivation in patients with B-cell lymphomas ...Europe PMC
europepmc.org
von S Kusumoto · · Zitiert von: 113 — ... Günter Fingerle-Rowson. 13Product Development Oncology, F. Hoffmann-La Roche Ltd., Basel, Switzerland; and. Find articles by Günter Fingerle-Rowson. Tina ... von S Kusumoto · · Zitiert von: 113 — ... Günter Fingerle-Rowson. 13Product Development Oncology, F. Hoffmann-La Roche Ltd., Basel, Switzerland; and. Find articles by Günter Fingerle-Rowson. Tina ...
Blocking Macrophage Migration Inhibitory Factor Protects ...uniupo.it
research.uniupo.it
von J Li · · Zitiert von: 42 — ... Suada Fröhlich, Pawel Szczęśniak, Philipp Lacher, Jörg Klug, Andreas Meinhardt, Günter Fingerle-Rowson, Rujun Gong, Zhihua Zheng, Anping Xu, Hui yao Lan.
Obinutuzumab or Rituximab Plus Cyclophosphamide, ...Medpage Today
clf1.medpagetoday.com
von U Vitolo · · Zitiert von: 356 — Tatsumi, Mikkel Z. Oestergaard, Michael Wenger, Günter Fingerle-Rowson, Olivier Catalani, Tina Nielsen,. Maurizio Martelli, and Laurie H.
Overall survival benefit in patients with rituximab-refractory ...elsevierpure.com
mdanderson.elsevierpure.com
von BD Cheson · · Zitiert von: 112 — ... John G. Gribben, Anne Lennard, Pieternella J. Lugtenburg, Günter Fingerle-Rowson, Federico Mattiello, Andrea Knapp, Laurie H. Sehn.
Pharmacokinetics, exposure, efficacy and safety of ...National Institutes of Health (.gov)
pubmed.ncbi.nlm.nih.gov
von E Gibiansky · · Zitiert von: 4 — Authors. Ekaterina Gibiansky , Leonid Gibiansky , Vincent Buchheit , Nicolas Frey , Michael Brewster , Günter Fingerle-Rowson , Candice Jamois ... von B Mathew · · Zitiert von: 48 — ... Huey,1 Aydogan Bulent,5 Brett Smith,5 Sundararajan Jayaraman,1,2 Narsa M. Reddy,3 Shekhar P. Reddy,3Günter Fingerle-Rowson,6 Richard Bucala,7 Steven M.
The Outcome of Renal Ischemia-Reperfusion Injury Is ...PLOS
journals.plos.org
von PF Mount · · Zitiert von: 34 — Günter Fingerle-Rowson,. Affiliation Department of Internal Medicine, University Hospital Cologne, Cologne, Germany. ⨯. Richard Bucala,.
Alle Infos zum Namen "Günter Fingerle-Rowson"
Verwandte Suchanfragen zu Günter Fingerle-Rowson
| Marcel Wolbers Andreas Meinhardt Kirsten Fischer | Philipp Lacher Clemens-Martin Wendtner Dominik Schumacher | Jörg Klug Suada Fröhlich Kaspar Rufibach |
Personen Vorname "Günter" (29119) Name |
sortiert nach Relevanz / Datum